NDAORALCAPSULE, EXTENDED RELEASE
Approved
Sep 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIBRELEASE is an extended-release oral capsule formulation of chlordiazepoxide, a benzodiazepine approved in 1983. The drug is used to treat anxiety disorders and alcohol withdrawal by enhancing GABA-mediated inhibition in the central nervous system. This reformulation extends dosing convenience for chronic anxiety management.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100) signals defensive positioning and potential team restructuring or consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LIBRELEASE offers limited growth opportunity given the LOE-approaching lifecycle and zero linked open positions. Roles focus on defensive commercial execution, generic price competition, and managed care negotiations rather than product expansion or innovation.
Brand ManagerProduct Manager
Worked on LIBRELEASE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.